Chimeric antigen receptor T ‐cells safety: A pharmacovigilance and meta‐analysis study-Reference-Cited by-同舟云学术

Chimeric antigen receptor T ‐cells safety: A pharmacovigilance and meta‐analysis study

Published:2021-06-23 Issue:9 Volume:96 Page:1101-1111
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Dolladille Charles¹²,Ederhy Stéphane³,Ezine Emilien⁴,Choquet Sylvain⁵,Nguyen Lee S.⁶⁷,Alexandre Joachim¹²,Moslehi Javid J.⁸,Dechartres Agnès⁹,Salem Joe‐Elie⁵⁸^ORCID

Affiliation:

1. Department of Pharmacology CHU de Caen Caen France

2. Université Caen Normandie, Medical School, EA 4650, Signalisation, Électrophysiologie et Imagerie des Lésions d'Ischémie‐reperfusion Myocardique Caen France

3. Hôpitaux Universitaires Paris‐Est, Assistance Publique‐Hôpitaux de Paris, Hôpital Saint Antoine, Service de Cardiologie, Unico, Unité de Cardio‐Oncologie APHP.6, GRC, Groupe de Recherche Clinique en Cardio Oncologie, INSERM 856 Université Pierre et Marie Curie Paris France

4. Department of Onco‐Dermatology CHU de Caen Caen France

5. Department of Hematology AP‐HP, Pitié‐Salpêtrière Hospital Paris France

6. CMC Ambroise Paré, Research & Innovation Neuilly‐sur‐Seine France

7. Department of Pharmacology, AP‐HP, Pitié‐Salpêtrière Hospital, CIC‐1901, INSERM Sorbonne Université, APHP.Sorbonne UNICO‐GRECO Cardio‐Oncology Program Paris France

8. Vanderbilt University Medical Center, Department of Medicine Cardio‐Oncology Program Nashville Tennessee USA

9. Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP‐HP, Sorbonne Université, Hôpital Pitié Salpêtrière Département de Santé Publique, Centre de Pharmacoépidémiologie de l'AP‐HP (Cephepi), CIC‐1901, F75013 Paris France

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26259

Reference34 articles.

1. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

2. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

3. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

4. A review of cancer immunotherapy toxicity

5. VigiBase, the WHO Global ICSR Database System: Basic Facts

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety assessment of anti-B cell maturation antigen chimeric antigen receptor T cell therapy: a real-world study based on the FDA adverse event reporting system database;Frontiers in Immunology;2024-09-03

2. PCSK9 Inhibitors and Infection-Related Adverse Events: A Pharmacovigilance Study Using the World Health Organization VigiBase;Drugs - Real World Outcomes;2024-07-02

3. Cytokine release syndrome after chimeric antigen receptor T cell therapy in patients with diffuse large B-cell lymphoma: a systematic review;Hematology, Transfusion and Cell Therapy;2024-07

4. A real-world pharmacovigilance study on cardiovascular adverse events of tisagenlecleucel using machine learning approach;Scientific Reports;2024-06-13

5. Toxicity of CAR T-Cell Therapy for Multiple Myeloma;Acta Haematologica;2024-05-08